Date:5/6/2009

---- --- Net Income (Loss) attributable to Solutia $(159) $(30) $1,454 ====== ===== ====== Basic and Diluted Loss per Share: Income (Loss) from Continuing Operations $(0.04) $(0.27) $11.96 Income (Loss) from Discontinued Operations, net of tax $(1.66) $(0.23) $1.95 Net Income (Loss) attributable to Solutia $(1.70) $(0.50) $(13.91) (a) Predecessor excludes unrecorded contractual interest expense of $5 in the two months ended February 28, 2008. SOLUTIA INC. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Dollars in millions, except per share amounts) (Unaudited) Successor --------- March 31, December 31, 2009 2008 ---- ---- ASSETS Current Assets: Cash and cash equivalents $35 $32 Trade receivables, net of allowances of $0 in 2009 and 2008 194 227 Miscellaneous receivables 91 110 Inventories 310 341 Prepaid expenses and other assets 75 85 Assets of discontinued operations 342 490 --- --- Total Current Assets 1,047 1,285
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Related biology technology :

1. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results